Summary of COVID-19 bemnifosbuvir studies
Studies
Meta Analysis
Hide extended summaries
MORNINGSKY RCT which was terminated early after enrolling only 216 of 1,386 planned participants. The trial did not meet its primary endpoint, with the bemnifosbuvir group having longer time to symptom improvement than placebo. However, compared to placebo, bemnifosbuvir was associated with a 71% relative risk reduction in COVID-19 hospitalizations and fewer COVID-19 complications and medically attended visits, despite no significant improvement in viral load.
Oct 2023, Future Virology, https://www.futuremedicine.com/doi/10.2217/fvl-2023-0115, https://c19p.org/horga
Phase 2 RCT investigating bemnifosbuvir for the treatment of 81 high-risk COVID-19 patients hospitalized with moderate disease. The trial was terminated early due to difficulties with enrollment. There was no significant difference between bemnifosbuvir and placebo for the primary outcome of disease progression or most secondary outcomes. However, viral load declined faster in the bemnifosbuvir group between days 2 and 8. All 3 deaths occurred in the placebo group. The safety profile was similar between groups. While results are very limited by small sample size and early termination, they suggest bemnifosbuvir may accelerate viral clearance and could play a role in preventing progression.
Jun 2023, Future Virology, https://www.futuremedicine.com/doi/10.2217/fvl-2023-0064, https://c19p.org/horga2
69 patient bemnifosbuvir early treatment RCT: 3% improved viral clearance (p=0.14).
RCT 100 mild/moderate COVID-19 patients showing no significant difference in nasopharyngeal viral load reduction between bemnifosbuvir (550mg or 1100mg twice daily for 5 days) and placebo groups.
Aug 2023, Microbiology Spectrum, https://journals.asm.org/doi/10.1128/spectrum.00077-23, https://c19p.org/boffito
1. Horga et al., Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)
207 patient bemnifosbuvir early treatment RCT: 71% lower hospitalization (p=0.05), 28% lower progression (p=0.49), 28% slower recovery, and 22% improved viral clearance (p=0.21).MORNINGSKY RCT which was terminated early after enrolling only 216 of 1,386 planned participants. The trial did not meet its primary endpoint, with the bemnifosbuvir group having longer time to symptom improvement than placebo. However, compared to placebo, bemnifosbuvir was associated with a 71% relative risk reduction in COVID-19 hospitalizations and fewer COVID-19 complications and medically attended visits, despite no significant improvement in viral load.
Oct 2023, Future Virology, https://www.futuremedicine.com/doi/10.2217/fvl-2023-0115, https://c19p.org/horga
2. Horga et al., Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19
83 patient bemnifosbuvir late treatment RCT: 86% lower mortality (p=0.24), 2% improved recovery (p=1), and 9% improved viral clearance (p=0.8).Phase 2 RCT investigating bemnifosbuvir for the treatment of 81 high-risk COVID-19 patients hospitalized with moderate disease. The trial was terminated early due to difficulties with enrollment. There was no significant difference between bemnifosbuvir and placebo for the primary outcome of disease progression or most secondary outcomes. However, viral load declined faster in the bemnifosbuvir group between days 2 and 8. All 3 deaths occurred in the placebo group. The safety profile was similar between groups. While results are very limited by small sample size and early termination, they suggest bemnifosbuvir may accelerate viral clearance and could play a role in preventing progression.
Jun 2023, Future Virology, https://www.futuremedicine.com/doi/10.2217/fvl-2023-0064, https://c19p.org/horga2
69 patient bemnifosbuvir early treatment RCT: 3% improved viral clearance (p=0.14).
RCT 100 mild/moderate COVID-19 patients showing no significant difference in nasopharyngeal viral load reduction between bemnifosbuvir (550mg or 1100mg twice daily for 5 days) and placebo groups.
Aug 2023, Microbiology Spectrum, https://journals.asm.org/doi/10.1128/spectrum.00077-23, https://c19p.org/boffito
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.